Utah Medical Products, Inc. Reports Earnings Decline Amidst Market Challenges

Shares of Utah Medical Products, Inc. (UTMD) fell by 4.6% following the company’s earnings report for the quarter ended December 31, 2024. This drop stands in contrast to the S&P 500 index, which saw a modest 0.5% increase during the same period. Over the past month, UTMD declined 0.4%, while the S&P 500 rose by 2.8%.

Stay updated with the latest market news through the Earnings Calendar.

Quarterly Performance Highlights

For the fourth quarter of 2024, Utah Medical reported earnings per share (EPS) of 86 cents. This represents a significant decrease of 27.4% compared to $1.18 in the fourth quarter of 2023.

Total revenues amounted to $9.2 million, reflecting a 25.8% decline from $12.3 million in the same quarter last year. This downturn was largely due to weaker sales across key product lines, notably a steep fall in revenues from PendoTECH OEM sales and reduced international distributor sales.

The net income for the quarter totaled $2.9 million, marking a 32.3% decline from $4.3 million in the prior year.

Annual Overview for Utah Medical

For the entire year, Utah Medical reported revenues of $40.9 million, down 18.6% from $50.2 million in 2023. The net income also saw a decline of 16.6%, dropping to $13.9 million from $16.6 million. EPS experienced a 13.4% drop, going from $4.57 to $3.96.

Financial Metrics and Margins

Despite the slump in revenues, Utah Medical managed to maintain relatively steady gross profit margins. The gross margin for the fourth quarter was 58.1%, slightly up from 57.6% in the same quarter a year prior. The overall gross margin for the year stood at 59%, a slight decrease from 59.8% in 2023.

Operating income for the fourth quarter fell 25.7% year-over-year to $2.9 million, while annual operating income was down 19% to $13.6 million. As of December 31, 2024, cash and investments totaled $83 million, compared to $92.9 million a year earlier.

Management Insights

Management identified three main factors behind the revenue decline: a $5.9 million drop in PendoTECH sales, decreased sales to international distributors, and a 12% decline in worldwide sales of the Filshie Clip System. In response to inflationary pressures, Utah Medical implemented efficiency measures such as workforce reductions and the cessation of a second production shift in Utah, which helped sustain profit margins.

Revenue Contributors and Challenges

The revenue decline was significantly impacted by a sharp drop in PendoTECH orders, responsible for 64% of the total revenue decrease. Additionally, Utah Medical recorded a $2.1 million decrease in sales to international distributors, primarily due to lower shipments of blood pressure monitoring kits to China. Sales of the Filshie Clip System also fell by 12% in both domestic and international markets.

The company encountered several challenges, including rising litigation and salary costs, as well as a newly introduced excise tax on share repurchases. Non-operating income was lower compared to the previous year, largely due to the absence of rental income from Ireland, which had contributed significantly in 2023.

Future Outlook for UTMD

Looking ahead, management projected another decline in total worldwide revenues for 2025, although at a slower rate than that experienced in 2024. While they foresee a continued dip in PendoTECH sales, there is hope for a slight rebound in sales from international distributors and the Filshie device.

Corporate Actions in 2024

In 2024, Utah Medical repurchased over 301,000 shares at an average price of $66.13 per share, totaling nearly $20 million. Additionally, the company announced an increase in its quarterly dividend to 30.5 cents per share, effective January 2025.

Noteworthy Stock Recommendation

Several financial experts have identified what they believe is a promising stock pick destined for a +100% increase in the near future. The Director of Research at Zacks Investment Research has highlighted one stock with significant potential that targets millennial and Gen Z audiences, generating almost $1 billion in revenue last quarter alone.

Find details on this top stock and others on our list.

For the latest stock recommendations, download 7 Best Stocks for the Next 30 Days.

Utah Medical Products, Inc. (UTMD): Comprehensive Stock Analysis Report.

Click here to read the full article on Zacks.com.

Zacks Investment Research

The views and opinions expressed herein are those of the author and do not necessarily reflect the views of Nasdaq, Inc.